Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Ocular Therapeutix reports positive pre-NDA FDA meeting for AXPAXLI

17 September 2026 · By · Wire by Fusion42

Published

17 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at glance.eyesoneyecare.com →

◆ Verified

Fusion42 · 17 September 2026 · Fusion42 review

Ocular Therapeutix successfully completed a pre-NDA meeting with the FDA for AXPAXLI, an intravitreal implant targeting wet age-related macular degeneration, and remains on track for NDA submission in Q4 2026 based on positive phase 3 data.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 16 Sep 2026 and 17 Sep 2026.

◆ ◆ The Wire takeaway

You can accelerate plans for wet AMD treatment development because an AXPAXLI FDA approval path is clarified and timed this year. That pushes competition and partnerships in sustained delivery retinal therapies into sharper focus.

◆ Coverage

2 sources · first reported 16 Sep 2026 · latest 17 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalwet-amdnanda-submissionocular-therapeutixclinical-trials